Developing a device to collect cells in vivo for therapeutic use
First written in FY2019. 2 of 5 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「Animal studies to date have confirmed that the device has good stem cell collection capacity. Pharmacodynamic studies using animal models of multiple diseases are being conducted to select the optimal indication, along with the preclinical studies required before initiating clinical trials.」
It has been explained that animal studies, disease model studies and preclinical studies for the therapeutic autologous cell collection device are continuing. - FY2022SoftenedAnnual report
「For PJ4-01, discussions are currently under way on a plan not to proceed beyond the Phase I trial, but as this remains undecided, it is listed as ND.」
For the therapeutic autologous cell collection device, discussions are under way on a plan not to proceed beyond the Phase I trial, indicating a weakening of the previous policy to continue development. However, the status is listed as undecided. - FY2021-Q2RestatedAnnual report
「At this newly established animal research facility, the Company plans to conduct screening of novel seeds, pharmacodynamic studies using laboratory animals, and studies of in vivo stem cell accumulation devices and other technologies.」
A plan was presented to conduct studies of in vivo stem cell accumulation devices and other technologies at the newly established animal research facility. - FY2020AdvancedAnnual report
「Animal studies to date have confirmed that the device has good stem cell collection capacity. Pharmacodynamic studies using animal models of multiple diseases are being conducted to select the optimal indication, along with the preclinical studies required before initiating clinical trials.」
For the therapeutic autologous cell collection device, good cell collection capacity was confirmed in animal studies, and pharmacodynamic studies in disease models and preclinical studies are under way. - FY2019First statedAnnual report
「A substance identified by the Company that attracts mesenchymal stem cells is incorporated into an implantable device, which is implanted subcutaneously in the patient for a specified period. The patient's own mesenchymal stem cells accumulated in the device are then collected and used for treatment.」
The concept involves accumulating and collecting the patient's own stem cells in an in-body device and using them for cell therapy.